Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine
- 1 January 2020
- journal article
- research article
- Vol. 18 (1) , 30-39
Abstract
Background - Viral reduction and inactivation of cell-derived biologicals is paramount for patients' safety and so viral reduction needs to be demonstrated to regulatory bodies in order to obtain marketing authorisation. Allogeneic human blood-derived biological medicinal products require special attention. APOSEC (TM), the secretome harvested from selected human blood cells, is a new biological with promising regenerative capabilities. We evaluated the effectiveness of inactivation of model viruses by methylene blue/light treatment, lyophilisation, and gamma irradiation during the manufacturing process of APOSEC (TM). Materials and methods - Samples of intermediates of APOSEC (TM) were acquired during the manufacturing process and spiked with bovine viral diarrhoea virus (BVDV), human immunodeficiency virus type 1 (HIV-1), pseudorabies virus (PRV), hepatitis A virus (HAV), and porcine parvovirus (PPV). Viral titres were assessed with suitable cell lines. Results - Methylene blue-assisted viral reduction is mainly effective against enveloped viruses: the minimum log(10) reduction factors for BVDV, HIV-1, and PRV were >= 6.42, >= 6.88, and >= 618, respectively, with no observed residual infectivity. Viral titres of both HAV and PPV were not significantly reduced, indicating minor inactivation of non-enveloped viruses. Lyophilisation had minor effects on the viability of several enveloped model viruses. Gamma irradiation contributes to the viral safety by reduction of enveloped viruses (BVDV: >= 2.42; HIV-1: 4.53; PRV: >= 4.61) and to some degree of non-enveloped viruses as seen for HAV with a minimum log10 reduction factor of 2.92. No significant reduction could be measured for the non-enveloped virus PPV (2.60). Discussion - Three manufacturing steps of APOSEC (TM) were evaluated under Good Laboratory Practice conditions for their efficacy at reducing and inactivating potentially present viruses. It could be demonstrated that all three steps contribute to the viral safety of APOSEC (TM).Keywords
This publication has 20 references indexed in Scilit:
- The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in ratsExperimental Neurology, 2015
- Challenge study of the pathogen reduction capacity of the THERAFLEX MB‐Plasma technologyVox Sanguinis, 2015
- Mononuclear cell secretome protects from experimental autoimmune myocarditisEuropean Heart Journal, 2013
- Inactivation of enveloped and non-enveloped viruses on seeded human tissues by gamma irradiationCell and Tissue Banking, 2011
- Anaphylactic reaction after methylene blue-treated plasma transfusionBritish Journal of Anaesthesia, 2011
- Evaluation of the minimal replication time of Cauliflower mosaic virus in different hostsVirology, 2010
- Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal productsTransfusion, 2009
- Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardiumEuropean Journal of Clinical Investigation, 2009
- Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (1997)Journal of Immunotherapy, 1997
- Viruses and the cell cycle1997